Propanc Biopharma, Inc. financial data

Symbol
PPCB on OTC
Location
Camberwell, Victoria, Australia
Fiscal year end
June 30
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152 % +8532%
Debt-to-equity 42.7 %
Return On Equity -601 % -1348%
Return On Assets -421 % +76%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.8M shares -98.1%
Common Stock, Shares, Outstanding 12.8M shares -98.1%
Entity Public Float 47.9K USD -88.7%
Common Stock, Value, Issued 12.8K USD -98.1%
Weighted Average Number of Shares Outstanding, Basic 12.3M shares +125106%
Weighted Average Number of Shares Outstanding, Diluted 12.3M shares +125106%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 222K USD -24.3%
General and Administrative Expense 61.4M USD +5582%
Operating Income (Loss) -61.7M USD -4274%
Nonoperating Income (Expense) -1.75M USD -221%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -63.4M USD -3146%
Income Tax Expense (Benefit) -275 USD +84%
Net Income (Loss) Attributable to Parent -63.4M USD -3376%
Earnings Per Share, Basic 20 USD/shares +98.9%
Earnings Per Share, Diluted 20 USD/shares +98.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.2K USD -30.4%
Other Assets, Current 8.83K USD
Assets, Current 8.76M USD +40596%
Property, Plant and Equipment, Net 2.36K USD
Operating Lease, Right-of-Use Asset 56.3K USD
Assets 18M USD +28144%
Accounts Payable, Current 1.07M USD -13.4%
Employee-related Liabilities, Current 687K USD +1.32%
Liabilities, Current 3.57M USD -12.9%
Operating Lease, Liability, Noncurrent 42.1K USD
Liabilities 3.61M USD -13.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.34M USD +14.1%
Retained Earnings (Accumulated Deficit) -130M USD -94.6%
Stockholders' Equity Attributable to Parent 14.4M USD
Liabilities and Equity 18M USD +28144%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.94M USD -723%
Net Cash Provided by (Used in) Financing Activities 2.53M USD +1071%
Net Cash Provided by (Used in) Investing Activities -2.49K USD
Common Stock, Shares Authorized 10B shares 0%
Common Stock, Shares, Issued 12.8M shares -98.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 591K USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 116K USD +4339%
Deferred Tax Assets, Valuation Allowance 23.8M USD +108%
Deferred Tax Assets, Gross 28.4M USD +136%
Operating Lease, Liability 62.1K USD
Depreciation 125 USD
Payments to Acquire Property, Plant, and Equipment 2.49K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -63.2M USD -2952%
Lessee, Operating Lease, Liability, to be Paid 62.6K USD +341%
Property, Plant and Equipment, Gross 27.8K USD +4.85%
Operating Lease, Liability, Current 20.5K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 24.1K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 27.8K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.78K USD -65.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 21.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 25.5M USD +181%
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 144M USD +135%
Deferred Tax Assets, Net of Valuation Allowance 23.8M USD +108%
Interest Expense 690K USD +29.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%